CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
CRISPR Therapeutics AGNASDAQ: CRSP
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$130.05M, compared with -$101.39M a year earlier. Trailing-twelve-month EBITDA was -$482.67M.
Context
- EBITDA amounted to 15911.3% of revenue in FY2025, up 14930.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 15 analysts of -$423.54M (+24.2%) for the fiscal year ending Dec 2026, a step up from the -62.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$130.05M-17.7% QoQ
- Last fiscal yearDec 2025
- -$558.49M-62.6% YoY
- LTMSep 2026
- -$482.67M-3.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -28.3% | +12.3% | +40.5 pp |
| 1 year | -62.6% | +24.2% | +86.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (558.49M) USD
- Year-over-year change
- -62.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (558.49M) | -62.6% |
| FY2024 | 2024-12-31 | (343.41M) | -162.4% |
| FY2023 | 2023-12-31 | (130.89M) | +79.1% |
| FY2022 | 2022-12-31 | (626.33M) | -257.6% |
| FY2021 | 2021-12-31 | 397.48M | — |
EBITDA vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's LTM Sep 2026 EBITDA of -$482.67M is the lowest of the 7 companies compared; the peer median is -$155.48M.
- Its year-over-year change of -3.6% is the 5th highest of 7, against a peer median of +35.5%.
- EBITDA amounts to 1917.5% of revenue for CRSP, versus a peer median of 203.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Jun 2026 | -$63.18M | +83.2% | — | 40.5% | |
| LTM Mar 2026 | -$100.08M | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$210.87M | +45.6% | — | 149.2% | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$482.67M | -3.6% | — | 1917.5% | |
| Peer median (excluding CRSP) | -$155.48M | +35.5% | — | 203.9% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 913.08M | 436K | 370M | 35M | 3.51M |
| Cost of Revenue | 101.18M | 110.25M | 130.25M | 110.25M | 232.96M |
| Gross Profit | 811.9M | (109.81M) | 239.75M | (75.25M) | (229.45M) |
| Gross Margin | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| Research & Development | 340.57M | 461.65M | 387.33M | 320.65M | 265.33M |
| Selling, General & Admin | 99.69M | 102.46M | 76.16M | 72.98M | 73.54M |
| Operating Expenses | 438.38M | 563.35M | 462.29M | 391.32M | 338.87M |
| Depreciation & Amortization | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| EBITDA | 397.48M | (626.33M) | (130.89M) | (343.41M) | (558.49M) |
| EBITDA Margin | 43.5% | -143653.2% | -35.4% | -981.2% | -15911.3% |
| Operating Income | 373.53M | (673.16M) | (222.54M) | (466.57M) | (568.32M) |
| Operating Margin | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6M | 22.66M | 71.82M | 103.9M | (9.65M) |
| Income Before Tax | 379.53M | (650.5M) | (150.72M) | (362.67M) | (577.97M) |
| Pre-Tax Margin | 41.6% | -149197.2% | -40.7% | -1036.2% | -16466.2% |
| Income Tax Expense | 1.87M | (325K) | 2.89M | 3.59M | 3.63M |
| Net Income | 377.66M | (650.18M) | (153.61M) | (366.25M) | (581.6M) |
| Net Margin | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| EPS (Basic) | 4.97 | (8.36) | (1.94) | (4.34) | (6.47) |
| EPS (Diluted) | 4.70 | (8.36) | (1.94) | (4.34) | (6.47) |
| Weighted Avg Shares | 75.95M | 77.75M | 79.22M | 84.36M | 89.93M |
| Weighted Avg Shares (Diluted) | 80.39M | 77.75M | 79.22M | 84.36M | 89.93M |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.